Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jared Haase
WB

Jared Haase

William Blair
Wall Street Analyst
★★★☆☆
#2087
on 13Foresight · ranked by our own returns
72%
Success Rate
+10.5%
Average Return
33 of 46 calls profitable · -321.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 72% of Jared Haase's ratings turned a profit when each position was held for 2 year — averaging +10.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.
Jared's Stock Coverage 19 ratings · 2026-11-14
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
LFCR
Lifecore Biomedical
 Oct 03, 2026 HOLD Buy
+49.2% avg upside
10 analysts
 — -2.3% ·
CRL
Charles River Labs
 Sep 24, 2026 BUY Strong Buy
-28.5% avg upside
36 analysts
 — +14.3% ·
ADUS
Addus Homecare
 Sep 14, 2026 BUY Strong Buy
+2.4% avg upside
19 analysts
 — +4.8% ·
LH
Labcorp Holdings
 Sep 11, 2026 BUY Strong Buy
-21.6% avg upside
38 analysts
 — +19.5% ·
FTRE
Fortrea Holdings Inc.
 Sep 10, 2026 HOLD Buy
+8.3% avg upside
13 analysts
 — +22.4% ·
INNV
InnovAge Holding
 Sep 09, 2026 HOLD Sell
-8.8% avg upside
12 analysts
 — -15.0% ·
CON
Concentra Group Holdings Parent, Inc.
 Sep 08, 2026 BUY Strong Buy
+0.7% avg upside
14 analysts
 — +24.3% ·
USPH
US Physical Therapy
 Aug 14, 2026 HOLD Strong Buy
+7.9% avg upside
12 analysts
 — +22.9% ·
AVAH
Aveanna Healthcare Holdings
 Aug 13, 2026 BUY Buy
-13.4% avg upside
19 analysts
 — +2.4% ·
DNA
Ginkgo Bioworks Holdings
 Aug 13, 2026 SELL Strong Sell
-32.3% avg upside
6 analysts
 — -41.6% ·
PNTG
Pennant Group
 Aug 05, 2026 BUY Strong Buy
-11.2% avg upside
9 analysts
 — -6.4% ·
EHC
Encompass Health
 Aug 05, 2026 BUY Strong Buy
-11.5% avg upside
23 analysts
 — +28.5% ·
CERT
Certara
 Aug 05, 2026 HOLD Buy
+21.4% avg upside
23 analysts
 — +46.4% ·
BTSG
BrightSpring Health Services, Inc.
 Jul 31, 2026 BUY Strong Buy
-0.5% avg upside
20 analysts
 — +18.4% ·
ICLR
Icon
 Jul 29, 2026 BUY Strong Buy
-1.8% avg upside
28 analysts
 — +9.2% ·
IQV
IQVIA Holdings
 Jul 28, 2026 BUY Strong Buy
-2.5% avg upside
40 analysts
 — +9.1% ·
DGX
Quest Diagnostics
 Jul 23, 2026 BUY Buy
-26.4% avg upside
34 analysts
 — +13.8% ·
MEDP
Medpace Holdings
 Jul 23, 2026 HOLD Buy
-17.3% avg upside
18 analysts
 — +7.2% ·
DH
Definitive Healthcare Corp
 Jul 02, 2026 HOLD Hold
+372.6% avg upside
19 analysts
 — +64.1% ·
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jared Haase — Frequently Asked Questions
How accurate are Jared Haase's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Jared's ratings were profitable over a one-year hold, with an average return of +10.5% per rating, or -321.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jared ranked on 13Foresight?
Jared Haase is currently ranked #2087 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jared cover?
Jared most recently has ratings on LFCR, CRL, ADUS, LH, FTRE, INNV, CON, USPH, AVAH, DNA, PNTG, EHC and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.